Related Experiment Video
Updated: Mar 6, 2026

Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
Effects of Transendocardial CD34+ Cell Transplantation on Diastolic Parameters in Patients with Nonischemic Dilated
Mojca Bervar1, Mirta Kozelj1, Gregor Poglajen2
1Department of Cardiology.
Insights
CD34+ cell transplantation improved diastolic function in nonischemic dilated cardiomyopathy patients with elevated filling pressures. This stem cell therapy enhanced exercise capacity and reduced NT-proBNP levels in this patient group.
Area of Science:
- Cardiology
- Regenerative Medicine
- Stem Cell Therapy
Background:
- Diastolic dysfunction is a key issue in nonischemic dilated cardiomyopathy (DCM).
- Elevated filling pressures (E/e' ≥ 15) in DCM patients correlate with myocardial scar and hibernation.
- Understanding the physiological basis of diastolic dysfunction is crucial for effective treatment.
Purpose of the Study:
- To evaluate the physiological background of diastolic parameters in nonischemic DCM patients.
- To assess the effects of transendocardial CD34+ cell transplantation on diastolic function.
- To determine if CD34+ cell therapy improves clinical outcomes in DCM.
Main Methods:
- 38 DCM patients with NYHA class III and LVEF < 40% underwent transendocardial CD34+ cell transplantation.
- Patients were divided into two groups based on baseline E/e' ratio (≥ 15 or < 15).
- Evaluated diastolic parameters, myocardial scar, hibernation, 6-minute walk distance, and NT-proBNP levels over a 1-year follow-up.
Main Results:
- Patients with higher baseline filling pressures (Group A) showed significant improvement in diastolic parameters (E/e') post-transplantation (p=0.005).
- Group A also demonstrated increased 6-minute walk distance (p=0.03) and decreased NT-proBNP levels (p=0.02).
- Diastolic dysfunction correlated with greater myocardial scar and hibernation in Group A.
Conclusions:
- Diastolic dysfunction in nonischemic DCM is linked to myocardial scar and hibernation.
- Transendocardial CD34+ cell transplantation shows potential to improve diastolic function and clinical outcomes in DCM patients.
- This stem cell therapy may offer a novel therapeutic approach for managing nonischemic DCM.
Abstract:
We sought to evaluate the physiological background and the effects of CD34+ cell transplantation on diastolic parameters in nonischemic dilated cardiomyopathy patients (DCM). We enrolled 38 DCM patients with NYHA class III and LVEF < 40% who underwent transendocardial CD34+ cell transplantation. Peripheral blood CD34+ cells were mobilized by G-CSF, collected via apheresis, and injected transendocardially in the areas of myocardial hibernation. Patients were followed for 1 year. At baseline, estimated filling pressures were significantly elevated (E/e' ≥ 15) in 18 patients (Group A), and moderately elevated (E/e '< 15) in 20 patients (Group B). The groups did not differ in age (54 ± 9 years vs. 52 ± 10 years; p = .62), gender (male: 85% vs. 78%; p = .57), or LVEF (31 ± 7% vs. 34 ± 6%; p = .37). When compared to Group B patients in Group A had more segments with myocardial scar (4.9 ± 2.7 vs. 2.7 ± 2.9; p = .03), myocardial hibernation (2.2 ± 1.6 vs. 0.9 ± 1.1; p = .02), and longer average local relaxation time on electroanatomical mapping (378 ± 41 ms vs. 333 ± 34 ms, p = .01). During follow-up there was an improvement in diastolic parameters in Group A (E/e': from 24.3 ± 12.1 to 16.3 ± 8.0; p = .005), but not in Group B (E/e': from 10.2 ± 3.7 to 13.2 ± 9.1; p = .19). Accordingly, in Group A, we found an increase in 6-minute walk distance (from 463 ± 83 m to 546 ± 91 m; p = .03), and a decrease in NT-proBNP (from 2140 ± 1743 pg/ml to 863 ± 836 pg/ml; p = .02). In nonischemic DCM, diastolic dysfunction appears to correlate with areas of myocardial scar and hibernation. Transendocardial CD34+ cell transplantation may improve diastolic parameters in this patient cohort. Stem Cells Translational Medicine 2017;6:1515-1521.
More Related Videos
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy

